List of Excipients in Branded Drug TOPCARE SLEEP AID

Generic Drugs Containing TOPCARE SLEEP AID

Company	Ingredient	NDC	Excipient
Topco Associates LLC	doxylamine succinate	36800-441	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Topco Associates LLC	doxylamine succinate	36800-441	CELLULOSE, MICROCRYSTALLINE
Topco Associates LLC	doxylamine succinate	36800-441	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
Topco Associates LLC	doxylamine succinate	36800-441	FD&C BLUE NO. 1 ALUMINUM LAKE
Topco Associates LLC	doxylamine succinate	36800-441	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in TOPCARE SLEEP AID?

# Of NDCs	Excipient
1	ACACIA
3	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
3	CELLULOSE, MICROCRYSTALLINE
3	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
2	FD&C BLUE NO. 1 ALUMINUM LAKE

Last updated: August 3, 2026

TopCare Sleep Aid is generally a private-label, immediate-release diphenhydramine hydrochloride product. Its commercial opportunity is driven by low-cost manufacturing, retail distribution, packaging, and differentiated delivery formats rather than patent exclusivity. The strongest excipient strategy is a simple, robust tablet or caplet platform with fast disintegration, low tooling cost, broad supplier availability, and strict control of allergens, colorants, and tablet defects.

TopCare Sleep Aid Excipient Strategy and Commercial Opportunities

What is TopCare Sleep Aid?

TopCare Sleep Aid is commonly marketed as an over-the-counter nighttime sleep aid containing diphenhydramine hydrochloride, usually at 25 mg per tablet or caplet. TopCare is a private-label retail brand associated with Topco Associates and supplied through retail pharmacy and grocery channels.

Diphenhydramine is an antihistamine used for occasional sleeplessness in adults and children age 12 and older under the applicable OTC labeling framework. FDA labeling directs consumers to take one 25 mg tablet at bedtime, with a maximum daily dose of 50 mg unless otherwise directed on the product label.[1]

The product category is mature and price-sensitive. Commercial differentiation depends on:

• Tablet and caplet manufacturing cost
• Disintegration and onset perception
• Swallowability
• Packaging and shelf presentation
• Retailer-specific positioning
• Sugar-free, dye-free, or gluten-free claims
• Alternative dosage forms such as liquids, softgels, and orally disintegrating tablets

What excipients are likely used in TopCare Sleep Aid?

The exact excipient list depends on the TopCare SKU, dosage form, contract manufacturer, and production site. A conventional diphenhydramine tablet typically uses excipients from the following functional classes.

Functional role	Common excipient options	Commercial purpose
Diluent	Microcrystalline cellulose, dibasic calcium phosphate, lactose, mannitol	Provides tablet mass and compression performance
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Promotes rapid breakup after ingestion
Lubricant	Magnesium stearate, sodium stearyl fumarate, stearic acid	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Improves appearance, handling, and swallowability
Sweetener or flavor	Sucralose, saccharin sodium, aspartame, flavors	Supports liquid and orally disintegrating formats
Suspending agent	Xanthan gum, cellulose derivatives, carbomer	Stabilizes liquid products
Preservative	Sodium benzoate, potassium sorbate, parabens	Controls microbial growth in aqueous products

A conventional low-cost tablet platform would likely use microcrystalline cellulose or dibasic calcium phosphate, a superdisintegrant, magnesium stearate, and colloidal silicon dioxide. A film-coated caplet would add hypromellose and polyethylene glycol.

The commercial objective is not to maximize the number of excipients. It is to achieve consistent hardness, low friability, clean compression, rapid disintegration, acceptable taste, and a low total cost of goods.

How should the excipient platform be designed?

Immediate-release tablet strategy

The most commercially efficient platform is an immediate-release compressed tablet or caplet.

A practical formulation architecture includes:

1. Diphenhydramine hydrochloride as the active ingredient.
2. A directly compressible diluent such as microcrystalline cellulose or dibasic calcium phosphate.
3. Croscarmellose sodium or crospovidone for rapid disintegration.
4. Colloidal silicon dioxide for flow control.
5. Magnesium stearate or sodium stearyl fumarate for lubrication.
6. An optional film coating for appearance and swallowing.

Microcrystalline cellulose supports direct compression and is widely available. Dibasic calcium phosphate can reduce formulation cost and improve tablet density, but it may produce a less smooth mouthfeel and can require closer control of compression conditions.

Crospovidone is attractive where rapid wicking and low gel formation are priorities. Croscarmellose sodium can provide strong swelling-based disintegration. Sodium starch glycolate is lower cost in some supply chains but may be more sensitive to overuse or excess compression force.

Caplet and film-coating strategy

A caplet can support a stronger consumer perception of quality than an uncoated tablet. It also reduces powdering and improves handling during packaging.

The coating should be evaluated for:

• Swallowability
• Color uniformity
• Moisture protection
• Coating weight
• Tablet identification
• Compatibility with retail packaging

A white or blue film coat is common in sleep-aid products, but dye-free positioning may support sales in selected channels. Titanium dioxide restrictions in certain markets can affect coating selection, particularly for products intended for European distribution.

Liquid formulation strategy

Diphenhydramine hydrochloride is suitable for liquid dosage forms because the hydrochloride salt is water soluble. A liquid product can target consumers who have difficulty swallowing tablets and can support higher shelf prices than a basic tablet.

A liquid platform would typically require:

• Purified water
• A sweetener system
• A viscosity modifier
• A flavor system
• A pH-control system
• A preservative system
• A chelating or antioxidant strategy if required by stability data

Potential excipient choices include sorbitol, glycerin, sucrose, sodium benzoate, potassium sorbate, citric acid, sodium citrate, xanthan gum, and cellulose-based viscosity modifiers.

The main development risks are preservative effectiveness, flavor masking, microbial control, sedimentation, and dose-measurement accuracy. A child-resistant package and calibrated dosing cup or syringe are important for risk management.

Orally disintegrating and chewable formats

An orally disintegrating tablet could command a premium if it delivers a meaningful convenience benefit. The platform would use mannitol or another water-soluble diluent, crospovidone or crospovidone-based co-processing, a flavor system, and a high-intensity sweetener.

The principal risks are bitterness, moisture sensitivity, tablet friability, and dose uniformity. Diphenhydramine has a strong medicinal taste, making taste masking a material development issue rather than a cosmetic preference.

Chewable tablets face similar taste and texture challenges. A chewable product may be commercially attractive for adult consumers who avoid swallowing tablets, but it should not be positioned for children without careful review of FDA labeling and misuse risks.

Softgel and gummy opportunities

A softgel can differentiate the product through a smooth dosage form and premium appearance. It requires a liquid fill compatible with the active ingredient, gelatin or vegetarian shell materials, plasticizers, and controlled sealing conditions.

Gummies create a stronger consumer proposition but carry higher formulation and manufacturing complexity. Key risks include:

• Moisture migration
• Active-content uniformity
• Dose loss during cooking or depositing
• Texture changes over shelf life
• Sugar and calorie content
• Child appeal and accidental ingestion risk
• Stability of the active in a high-moisture matrix

For a mature diphenhydramine product, gummies may create more regulatory and safety exposure than incremental commercial value. A sugar-free lozenge or orally disintegrating tablet may provide a lower-risk alternative.

What regulatory status applies to TopCare Sleep Aid?

TopCare Sleep Aid is generally regulated as an OTC drug rather than as a prescription NDA product. Diphenhydramine products used as nighttime sleep aids fall under FDA’s OTC framework for internal analgesic, antipyretic, and antirheumatic products and sleep-aid labeling requirements, including 21 C.F.R. § 338.50 and related Drug Facts requirements.[2]

Regulatory issue	Commercial implication
OTC drug status	Product must comply with applicable monograph or other FDA authorization pathway
Drug Facts labeling	Active ingredient, purpose, warnings, directions, and inactive ingredients must be correctly stated
cGMP compliance	Manufacturing, testing, packaging, and recordkeeping must comply with 21 C.F.R. Parts 210 and 211
NDC registration	Product and establishment information must be maintained through FDA registration and listing requirements
Stability	Finished product must meet specifications through labeled shelf life
Packaging	Child-resistant packaging may be required depending on package and distribution configuration
Adverse-event reporting	Serious adverse events must be reported under applicable OTC requirements

The FDA’s OTC monograph system does not create the same exclusivity structure as an approved prescription NDA. A compliant competitor can generally enter with the same active ingredient, strength, dosage form, and permitted claims.

What patents protect TopCare Sleep Aid?

The core diphenhydramine sleep-aid product has no meaningful composition-of-matter exclusivity. Diphenhydramine is an old, widely available active ingredient. A standard 25 mg immediate-release tablet is unlikely to have defensible patent protection based solely on its active ingredient or ordinary excipients.

IP category	Likely position for a standard TopCare product
Active-ingredient patent	Expired or not commercially relevant
Standard tablet formulation patent	Unlikely to provide meaningful protection
Method-of-use patent	Limited commercial value for conventional OTC sleep-aid use
Manufacturing process patent	Possible, but generally narrow and difficult to enforce
Packaging patent	Possible for specialized systems
Trademark	TopCare brand protection is commercially relevant
Trade secret	Supplier, process, coating, flavor, and quality-control know-how may be important

The relevant competitive barrier is therefore manufacturing execution and retail access, not patent exclusion. There is no conventional Paragraph IV pathway for a private-label OTC product of this type, and TopCare Sleep Aid is not typically an Orange Book-listed prescription product. The Orange Book does not function as the primary competitive registry for a conventional OTC monograph drug.[3]

When does TopCare Sleep Aid lose exclusivity?

TopCare Sleep Aid does not have a conventional prescription-drug exclusivity period. Its commercial exclusivity comes from the TopCare trademark, retailer relationships, shelf placement, packaging, and supply arrangements.

A competitor can enter with a comparable diphenhydramine product if it complies with FDA requirements. There is no expected patent cliff comparable to those affecting branded prescription drugs.

The main timing risks are operational:

• Loss of a retail contract
• Supplier interruption
• Formulation change requiring stability work
• Packaging redesign
• FDA inspection findings
• Product recall
• Retailer migration to a competing private-label supplier

What commercial opportunities exist for excipient suppliers?

Cost-reduction programs

Excipient suppliers can pursue volume contracts for:

• Direct-compression microcrystalline cellulose
• Dibasic calcium phosphate
• Croscarmellose sodium
• Crospovidone
• Magnesium stearate
• Hypromellose coating systems
• Colloidal silicon dioxide

The most attractive proposals will reduce total manufacturing cost without increasing tablet defects, compression downtime, or dissolution variability.

Clean-label and allergen-positioned products

Dye-free, lactose-free, sugar-free, and gluten-free formulations can support differentiated retailer SKUs. These claims must be supported by supplier controls and finished-product documentation.

A clean-label positioning may be more commercially valuable in premium pharmacy, grocery, and e-commerce channels than in the lowest-price segment.

Pediatric and senior-oriented delivery systems

Senior-focused opportunities include easy-open but compliant packaging, smaller tablets, film-coated caplets, and orally disintegrating tablets. Pediatric positioning requires particular caution because diphenhydramine sleep-aid use is not intended for young children under standard OTC labeling.

Private-label line extensions

Potential extensions include:

Product concept	Opportunity	Main risk
Diphenhydramine liquid	Swallowing difficulty and family-size format	Taste, preservation, dosing errors
Sugar-free liquid	Diabetic and calorie-conscious consumers	Sweetener aftertaste and stability
Dye-free caplet	Clean-label positioning	Appearance and retailer differentiation
Orally disintegrating tablet	Convenience and premium pricing	Bitterness and moisture sensitivity
Softgel	Premium dosage-form perception	Fill compatibility and higher COGS
Nighttime combination product	Broader symptom positioning	Additional actives, labeling, and interaction risks

How strong is the patent estate for TopCare Sleep Aid?

The patent estate is weak for a standard diphenhydramine tablet. The defensible assets are more likely to be:

• TopCare trademark rights
• Retail distribution agreements
• Approved supplier status
• Formulation and process know-how
• Stability data
• Packaging configurations
• Private-label manufacturing capacity

A new formulation could support patent filings only if it demonstrates a specific, non-obvious technical result, such as improved taste masking, enhanced stability, controlled release, or a distinctive delivery system. A routine substitution of one diluent or disintegrant for another would face a weak patentability position.

Which companies are challenging TopCare Sleep Aid?

Competition comes primarily from other OTC and private-label products rather than from patent litigation. Relevant competitors include:

• Retailer-branded diphenhydramine products
• Benadryl-branded diphenhydramine products
• Unisom products containing doxylamine or other sleep-aid ingredients
• Store-brand doxylamine products
• Melatonin products
• Doxylamine and diphenhydramine combination products
• Non-drug sleep-support products

Doxylamine products compete on perceived potency and longer duration, while melatonin products compete on consumer preference for a non-antihistamine sleep product. These products differ in active ingredient, regulatory positioning, consumer expectations, and adverse-effect profiles.

What litigation and licensing issues affect the product?

No product-specific patent litigation or biosimilar dispute is expected for a conventional TopCare diphenhydramine sleep-aid tablet. Biosimilar risk is not applicable because diphenhydramine is a small-molecule OTC active ingredient, not a biologic.

Licensing economics are also limited. The principal commercial agreements are likely to involve:

• Private-label manufacturing
• Retail supply
• Distribution
• Packaging
• Excipient sourcing
• Brand and trademark rights

A formulation developer could create licensing value through a differentiated dosage form, but a standard immediate-release tablet would generally be more suitable for contract manufacturing than for a royalty-bearing platform license.

Key Takeaways

• TopCare Sleep Aid is generally a private-label diphenhydramine hydrochloride OTC product.
• The strongest base formulation is a low-cost immediate-release tablet or film-coated caplet.
• Microcrystalline cellulose, dibasic calcium phosphate, croscarmellose sodium, crospovidone, magnesium stearate, and hypromellose are commercially relevant excipient options.
• Liquid, orally disintegrating, softgel, and gummy formats offer line-extension opportunities, but taste, stability, dosing, and child-safety risks increase with formulation complexity.
• The product has little practical patent exclusivity and no conventional Orange Book or Paragraph IV strategy.
• Commercial defensibility comes from retailer access, cost control, supply reliability, quality systems, packaging, and trademark rights.
• The highest-value excipient opportunity is likely a robust, dye-free or sugar-free tablet platform with validated rapid disintegration and low manufacturing cost.

FAQs

Is TopCare Sleep Aid the same as Benadryl?

TopCare Sleep Aid and Benadryl products may contain the same active ingredient, diphenhydramine hydrochloride, but they can differ in excipients, dosage form, packaging, labeling, and inactive-ingredient profile.

Can diphenhydramine be formulated as a gummy?

Yes, but gummy development introduces moisture, dose-uniformity, texture, stability, and accidental-ingestion risks. A chewable or orally disintegrating tablet may offer a simpler regulatory and manufacturing pathway.

Are excipients in a TopCare tablet patent protected?

Routine excipients such as microcrystalline cellulose, magnesium stearate, and common superdisintegrants are not individually protected for ordinary use. A specific formulation could be patentable only if it produces a non-obvious technical result.

What is the most commercially attractive TopCare Sleep Aid extension?

A dye-free, sugar-free film-coated caplet is likely to offer the best balance of consumer differentiation, manufacturing simplicity, regulatory manageability, and retail compatibility.

Is TopCare Sleep Aid suitable for children?

Standard OTC nighttime sleep-aid labeling for diphenhydramine generally limits use to adults and children 12 years and older. Any pediatric-oriented product strategy requires separate review of labeling, dosing, packaging, and safety requirements.[1]

References

1. DailyMed. (n.d.). Diphenhydramine hydrochloride sleep aid: Drug label information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Section 338.50: Labeling of antihistamine drug products for over-the-counter human use.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
4. U.S. Food and Drug Administration. (2024). Over-the-counter monograph drugs. FDA.
5. U.S. Food and Drug Administration. (2024). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Parts 210 and 211.